Find out what made these stocks miss out on a rally.
News & Analysis: Spark Therapeutics
The company agreed to be purchased at a hefty premium.
Investors were encouraged by trade and merger news today.
A $4.8 billion buyout by Roche sparks a celebration for the small biotech's investors.
ONCE earnings call for the period ending December 31, 2018.
Here's how calamities we witnessed in 2018 will hound biotech investors in the new year.
The company’s latest trial data failed to ignite a rally in its share price.
This gene therapy biotech has its sights set on a second commercial-stage opportunity
Is there a light at the end of the tunnel?
Find out which of these stocks had the biggest losses.